Out of 76 sequenced lung cancer samples, 36.1% of EGFR mutations were missense along exon 19, 50.0% were missense along exon 21, 5.6% along exon 20 and 8.3% along exon 18 (Fig. 2A). The gene discussed is EGFR; the disease is lung carcinoma.